Who makes [14C]BMS-986177 Solution for Infusion?

[14C]BMS-986177 Solution for Infusion is developed by Bristol-Myers Squibb.

What development phase is [14C]BMS-986177 Solution for Infusion in?

[14C]BMS-986177 Solution for Infusion is in Phase 1.

Last reviewed 2026-04-19 · How we verify

[14C]BMS-986177 Solution for Infusion

Bristol-Myers Squibb · Phase 1 active Small molecule

At a glance

Generic name	[14C]BMS-986177 Solution for Infusion
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]BMS-986177 Solution for Infusion CI brief — competitive landscape report
[14C]BMS-986177 Solution for Infusion updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI